THE COST OF ANGINA-PECTORIS IN SWEDEN

被引:15
作者
ANDERSSON, F
KARTMAN, B
机构
[1] Astra Hässle AB, Mölndal
[2] Department of Economics, Gothenburg University, Gothenburg
关键词
D O I
10.2165/00019053-199508030-00006
中图分类号
F [经济];
学科分类号
02 ;
摘要
A survey of 402 Swedish patients with angina pectoris was performed to estimate the annual direct medical costs, and nonmedical costs, of a typical Swedish angina pectoris patient, and to identify those variables having the greatest impact on the direct medical costs. Data regarding the consumption of healthcare services over a 3-month period were collected through telephone interviews conducted by trained nurses at a medical marketing agency. The data were multiplied by 4 to obtain an estimate of the annual resource consumption. The annual direct medical cost of angina pectoris was estimated at 40 052 Swedish kronor (SEK; $US1 approximate to SEK7.20, March 1995) per patient, comparable with the cost of a myocardial infarction. As expected, however, the severity of angina pectoris was important in determining the direct medical cost. The significant variables explaining variations in direct costs were (in order of importance): (i) whether the patient had undergone cardiovascular surgery; (ii) whether the patient was treated by a general practitioner or an internist; (iii) the number of years since first diagnosis of angina pectoris; and (iv) whether the patient's angina pectoris was characterised as stable or unstable. The annual nonmedical cost of angina pectoris per patient was estimated at SEK38 225. The relatively high costs of angina pectoris underline the importance of health economic evaluations of various diseases and medical interventions.
引用
收藏
页码:233 / 244
页数:12
相关论文
共 16 条
[1]  
SR, PharmacoEconomics, 6, (1994)
[2]  
Ejdeback J., Rastam L., Angina pectoris, Läkemedelsboken 93/94, (1993)
[3]  
Levin L-A, Myocardial infarction - costs and benefits of prevention and treatments [dissertation], (1991)
[4]  
Johannesson M., Dahlof B., Lindholm L.H., Et al., The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish trial in old patients with hypertension, J Intern Med, 234, (1993)
[5]  
Johannesson M., Borgquist L., Jonsson B., The costs of treating hypertension in Sweden, Scand J Prim Health Care, 9, (1991)
[6]  
Greenterg R.N., Overview of patient compliance with medication dosing: a literature review, Clin Ther, 6, (1984)
[7]  
Hodgson T.A., Cost-of-illness in cost-effectiveness analysis: a review of the methodology, PharmacoEconomics, 6, (1994)
[8]  
Nilsson P., Kandell-Collen A., Lindholm L.H., Et al., Care of hypertensives in Dalby: organisation and health economic aspects, J Hum Hypertens, 7, (1993)
[9]  
Persson U., Silverberg R., Lindgren B., Et al., Direct medical costs of stroke for a Swedish population, Int J Technol Assess Health Care, 6, (1990)
[10]  
Terent A., Marke L-A, Asplund K., Et al., Costs of stroke in Sweden: a national perspective, Stroke, 25, (1994)